Symptom Reduction and Suicide Risk Among Patients Treated With Placebo in Antipsychotic Clinical Trials: An Analysis of the Food and Drug Administration Database
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The assumption that psychotic patients assigned to placebo in clinical trials of antipsychotics are exposed to substantial morbidity and mortality is not based on data about what actually happens to such patients. This study assesses symptoms and risks of suicide and suicide attempts in psychotic patients assigned to receive placebo in clinical trials. METHOD: The authors used the Food and Drug Administration database to assess suicides, suicide attempts, and psychotic symptom reduction in clinical trials of three new antipsychotics. RESULTS: Among 10,118 participating patients, 26 committed suicide and 51 attempted suicide. Rates of suicide and attempted suicide did not differ significantly between the placebo-treated and the drug-treated groups. Annual rates of suicide and attempted suicide based on patient exposure years were 1.8% and 3.3%, respectively, with placebo; 0.9% and 5.7% with an established antipsychotic; and 0.7% and 5.0% with a new antipsychotic. Symptom reduction was 16.6% with new antipsychotics (N=1,203), 17.3% with established antipsychotics (N=261), and 1.1% with placebo (N=462). CONCLUSIONS: These data may help inform discussions about the use of placebo in antipsychotic clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
“1%, a rate not appreciably different from that for use of atypical antipsychotic drugs in the study by Khan et al.(11) Given that the selection criteria for the InterSePT study population required evidence for a high risk of suicide, a higher rate of treatment-emergent suicidal behaviors was expected than was describe…”
BackgroundResultInfluentialCusack, K., Jonas, D. E., Forneris, C. A., Wines, C., Sonis, J., Middleton, J. C., Feltner, C., Brownley, K. A., Olmsted, K. R., Greenblatt, A., et al. (2016) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.10.003 · Cited by 865
Alper, K., Schwartz, K. A., Kolts, R. L., & Khan, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.023 · Cited by 522
Self-citationRanjekar, P. K., Hinge, A., Hegde, M. V., Ghate, M., Kale, A., Sitasawad, S., Wagh, U. V., Debsikdar, V. B., & Mahadik, S. P. (2003) · Psychiatry Research · doi:10.1016/s0165-1781(03)00220-8 · Cited by 395
Suicide risk in schizophrenia: learning from the past to change the future
Pompili, M., Amador, X. F., Girardi, P., Harkavy-Friedman, J., Harrow, M., Kaplan, K., Krausz, M., Lester, D., Meltzer, H. Y., Modestin, J., et al. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-10 · Cited by 358
Peet, M., & Horrobin, D. F. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00048-6 · Cited by 329
Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology
Leon, A. C., Mallinckrodt, C. H., Chuang-Stein, C., Archibald, D. G., Archer, G. E., & Chartier, K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.020 · Cited by 303
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database
Khan, A., Leventhal, R. M., Khan, S., & Brown, W. A. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00354-8 · Cited by 190
Self-citationTreatment response after relapse in a placebo-controlled maintenance trial in schizophrenia
Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.030 · Cited by 110
“Long-term consequences of exposure to placebo are therefore largely unknown, making informed decisions difficult (Khan et al., 2001).”
BackgroundPeet, M. (2003) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.08.020 · Cited by 103
Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
Pompili, M., Baldessarini, R., Forte, A., Erbuto, D., Serafini, G., Fiorillo, A., Amore, M., & Girardi, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101700 · Cited by 78
“A meta-analysis of an FDA database of controlled trials found that rates of suicide and attempts (as incidentally reported adverse outcomes) did not differ significantly between drug- and placebo-treated patients among drugs that included olanzapine, risperidone, and quetiapine [51].”
BackgroundSuicidal Behavior in Mood Disorders: Response to Pharmacological Treatment
Tondo, L., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0715-0 · Cited by 71
Zisook, S., Kasckow, J. W., Lanouette, N. M., Golshan, S., Fellows, I., Vahia, I., Mohamed, S., & Rao, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05699gre · Cited by 45
Healy, D. (2006) · Global Pharmaceuticals · doi:10.1215/9780822387916-003 · Cited by 35
The role of psychopharmacology in suicide prevention
Saunders, K. E. A., & Hawton, K. (2009) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00000427 · Cited by 34
“Khan et al. (2001) studied over 10,000 patients registered on the FDA database to compare suicide risk in those taking placebo vs first generation vs second generation antipsychotics.”
BackgroundEnhancing clinical trial design of interventions for posttraumatic stress disorder
Leon, A. C., & Davis, L. L. (2009) · Journal of Traumatic Stress · doi:10.1002/jts.20466 · Cited by 26
Design characteristics that influence attrition in geriatric antidepressant trials: meta‐analysis
Heo, M., Papademetriou, E., & Meyers, B. S. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2211 · Cited by 18
Metadata
- Authors
- Khan, A., Khan, S. R., Leventhal, R. M., & Brown, W. A.
- Venue
- American Journal of Psychiatry
- Published
- 2001-09-01
- Volume
- 158
- Issue
- 9
- Pages
- 1449-1454
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1987417156
- Cited by
- 130
- References
- 0
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.